Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09KTS
|
|||
| Former ID |
DNCL002550
|
|||
| Drug Name |
Ibrutinib
|
|||
| Synonyms |
PCI-32765; Ibrutinib (BTK inhibitor)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1; ICD-9: 200.4] | Approved | [1], [2], [3] | |
| B-cell non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 3 | [4] | ||
| Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 3 | [4] | ||
| Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Phase 3 | [4] | ||
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 3 | [4] | ||
| Pancreatic cancer [ICD-11: 2C10] | Phase 3 | [4] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [4] | ||
| Company |
Janssen Biotech; Pharmacyclics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H24N6O2
|
|||
| Canonical SMILES |
C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
|
|||
| InChI |
1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1
|
|||
| InChIKey |
XYFPWWZEPKGCCK-GOSISDBHSA-N
|
|||
| CAS Number |
CAS 936563-96-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
49837088, 57132050, 123051065, 124898784, 124898785, 136940589, 136961336, 137472671, 152258295, 160647134, 162202692, 163312254, 163679284, 164045821, 164193915, 165245631, 171572071, 172919350, 174007139, 175267389, 176250273, 178103494, 184611713, 184816969, 189025882, 198993428, 215784879, 223375297, 223485070, 223600477, 223685684, 223704724, 224184328, 226558356, 242585660, 247523488, 249736825, 251971042, 252088605, 252110183, 252160516, 252215999, 252451849
|
|||
| ChEBI ID |
CHEBI:76612
|
|||
| ADReCS Drug ID | BADD_D01119 | |||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6912). | |||
| REF 2 | Janssen's IMBRUVICA (ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenstrom's Macroglobulinemia. Janssen-Cilag International NV (Janssen). Jul 10, 2015. | |||
| REF 3 | ClinicalTrials.gov (NCT01833039) An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma. U.S. National Institutes of Health. | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.